Skip to main content

Advertisement

SpringerLink
Log in

Duration of Chemotherapy for Early Stage Breast Cancer: Have We Reached the Limit? What is the Survival Impact of Amenorrhea?

  • Clinical Trials Report
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Fisher B, Brown A, Dimitrov N, et al.: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with Tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990, 8:1483–1496.

    CAS  PubMed  Google Scholar 

  2. Henderson I, Berry D, Demetri G, et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976–983.

    Article  CAS  PubMed  Google Scholar 

  3. Wood W, Budman D, Korzun A, et al.: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Eng J Med 1994, 330:1253–1259.

    Article  CAS  Google Scholar 

  4. LHRH-Agonists in Early Breast Cancer Overview Group: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711–1723.

    Article  Google Scholar 

  5. Davidson N, O’Neill A, Vukov A, et al.: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005, 23:5973–5982.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rena Rowan Breast Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Rebecca L. Hirsh MD & Kevin R. Fox MD

Authors
  1. Rebecca L. Hirsh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin R. Fox MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin R. Fox MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirsh, R.L., Fox, K.R. Duration of Chemotherapy for Early Stage Breast Cancer: Have We Reached the Limit? What is the Survival Impact of Amenorrhea?. Curr. Treat. Options in Oncol. 11, 59–62 (2010). https://doi.org/10.1007/s11864-010-0123-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-010-0123-3

Keywords

Search

Navigation